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There are concerns that emerging resistance to ﬂuoroquinolones (FQ) may be leading to increasing rates of
gram-negative rod (GNR) bacteremia in hematopoietic cell transplant (HCT) recipients. We set out to describe
time trends in the incidence rates of GNR bacteremia and FQ-resistant GNR bacteremia in HCT recipients
during an era of levoﬂoxacin prophylaxis. We conducted a longitudinal retrospective study of adults un-
dergoing allogeneic HCT between 2003 and 2012 at the Seattle Cancer Care Alliance (SCCA). Annual trends in
the incidence rates of GNR bacteremia and FQ-resistant GNR bacteremia through 100 days after trans-
plantation were assessed using Poisson regression. Cox proportional hazards regression was used to compare
30-day mortality between patients with FQ-resistant and those with FQ-sensitive GNR bacteremia. Of the
2306 patients included in this cohort, 280 (12.1%) had GNR bacteremia. The incidence rates of GNR bacter-
emia and FQ-resistant GNR bacteremia increased from 2003 to 2009 and decreased afterwards; however, the
overall annual trends were not signiﬁcant (incidence rate ratio [IRR], 1.01; 95% conﬁdence interval [CI], .98 to
1.05; IRR, 1.01; 95% CI, .95 to 1.08, respectively). FQ-resistant GNR bacteremia was associated with increased
mortality compared with FQ-sensitive GNR bacteremia, even after adjustment for underlying disease severity,
conditioning regimen, and age at transplantation (hazard ratio, 2.11; 95% CI, 1.06 to 4.23). On average, rates of
FQ-resistant GNR bacteremia have not signiﬁcantly changed over 10 years of FQ prophylaxis, although FQ-
resistant GNR bacteremia is associated with increased mortality compared with FQ-sensitive GNR bacteremia.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bacterial bloodborne infections are a common cause of
morbidity and mortality among allogeneic hematopoietic
cell transplant (HCT) patients, occurring in up to 55% of this
population [1]. Gram-negative rod (GNR) bacteremia affects
between 5% and 11% of patients and is associated with higher
case fatality than bacteremia caused by gram-positive or-
ganisms [2-4]. The majority of cancer/transplantation cen-
ters worldwide utilize antibiotic prophylaxis duringdgments on page 544.
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ty for Blood and Marrow Transplantation.neutropenia to prevent GNR bacteremia and associated
mortality in these highly immunocompromised patients.
International guidelines currently recommend the use of
ﬂuoroquinolones (FQ) for neutropenic prophylaxis in cancer
and HCT patients whose absolute neutrophil count is antic-
ipated to decrease to 500/mL for at least 7 days [5-7], as FQ
have been shown to reduce the incidence of infectious
complications in neutropenic patients and to decrease mor-
tality [8]. Levoﬂoxacin is the most frequently used agent
because of its excellent bioavailability, oral formulation, and
convenient once daily dosing [9]. Although FQ prophylaxis
has given ﬂexibility to outpatient cancer care, recent guide-
lines warn that resistance should be monitored because of
increasing FQ resistance worldwide [5]. Recent studies have
suggested that the incidence of GNR bacteremia is increasing
in HCT recipients [1,10], including 1 study at our center [11].
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ment of associated antimicrobial resistance may play a major
role in this change [10]. However, studies that have examined
the emergence of FQ-resistant GNR bacteremia among pop-
ulations who receive FQ prophylaxis have been inconsistent
[1,10,12]. It is also unknown if HCT recipients who develop
FQ-resistant GNR bacteremia have an associated increased
mortality when compared with patients who develop FQ-
sensitive GNR bacteremia. Data from other populations
have demonstrated higher mortality associated with anti-
microbial resistant infections [13], but most studies in HCT
recipients have had insufﬁcient power to address this
important question.
Levoﬂoxacin became standard practice for neutropenic
prophylaxis for adult HCT recipients at the Seattle Cancer
Care Alliance (SCCA)/Fred Hutchinson Cancer Research Cen-
ter (FHCRC) in August 2002. The short-term impact of the
change from ceftazidime to levoﬂoxacin prophylaxis was
addressed in a previous study at our center [9], but data on
GNR infections after long-term use of levoﬂoxacin prophy-
laxis as the standard of care have yet to be examined. To
better understand trends in GNR bacteremia and FQ-
resistant GNR bacteremia during this era of levoﬂoxacin
prophylaxis, we conducted a longitudinal retrospective study
of allogeneic HCT recipients who underwent transplantation
between January 2003 and December 2012. Our primary goal
was to determine annual trends in the incidence of GNR
bacteremia and FQ-resistant GNR bacteremia during the ﬁrst
100 days after transplantation in this cohort. In addition, we
compared 30-daymortality betweenHCT recipients with FQ-
resistant GNR bacteremia and those with FQ-sensitive GNR
bacteremia.METHODS
Study Population
All adults (18 years) who underwent an allogeneic HCT between
January 1, 2003 and December 31, 2012 at the SCCA/FHCRC were eligible for
inclusion in this study. For those patients who had multiple allogeneic
transplantations during the study period of interest, each transplantation
was considered separately. The study was approved by the FHCRC institu-
tional review board.Microbiologic Assessment and Antibacterial Prophylaxis
Center guidelines recommend that 2 sets of anaerobic and aerobic blood
cultures are drawn when a patient presents with a fever, followed by daily
blood cultures until an alternative source of the fever is identiﬁed or the
patient defervesces. Although standard recommendations exist, blood cul-
tures are ultimately drawn at the discretion of the health care teams, with
the exception of surveillance blood cultures that are routinely drawn per
protocol from patients who are treated with high-dose glucocorticoids
(.5 mg/kg). Because steroids are known to blunt febrile responses [14],
these surveillance cultures are drawn biweekly while inpatient and weekly
on outpatient discharge, and they are discontinued after tapering of glu-
cocorticoids to<.5 mg/kg. The majority of blood cultures are drawn through
central venous catheters or ports during post-HCT care.
HCT recipients at the SCCA/FHCRC receive 750 mg levoﬂoxacin daily for
prophylaxis at the start of neutropenia until neutrophil recovery (absolute
neutrophil count [ANC] > 500/mL); levoﬂoxacin is restarted for patients
whose ANC drops below 500/mL at other points during their post-
transplantation care. Ceftazidime is the recommended empiric ﬁrst-line
antibiotic for neutropenic fever; the addition of vancomycin is only
recommended if febrile patients also have high-grade mucositis. All
patients also receive antimicrobial prophylaxis with trimethoprim-
sulfamethoxazole, dapsone, or atovaquone for Pneumocystis jirovecii pro-
phylaxis after ANC recovery, ﬂuconazole or an extended spectrum azole
(voriconazole or posconazole) for antifungal prophylaxis, and acyclovir or
valacyclovir for herpes simplex/varicella zoster virus prophylaxis. All pa-
tients undergo cytomegalovirus preemptive surveillance/therapy, as has
been previously described [11]. Of note, the standard preemptivecytomegalovirus surveillance strategy changed from pp65 antigenemia to
DNA measurement by quantitative PCR in 2007.
Data Collection
Data were extracted from prospectively collected databases maintained
by the FHCRC that include demographic, laboratory, and clinical data from
all patients undergoing HCT. Additional microbiologic data were collected
through electronic medical record review. Allogeneic HCT recipients remain
at the center for a minimum of 100 days after transplantation, assuring
complete post-transplantation data capture during this time period.
Deﬁnitions
GNR bacteremia was deﬁned as the isolation of any GNR from a blood
culture. To reduce the likelihood of misclassifying repeat blood cultures
from a primary event, positive cultures for the same organism collected
14 days from a prior positive culture were considered part of the primary
event. Additionally, early post-transplantation GNR events were excluded if
the same organism was isolated in a pretransplantation culture in a similar
14-day window. Positive cultures for different bacterial species, even if they
occurred within 14 days from a documented GNR event, were considered
unique events. Cultures that isolated multiple GNR organisms on the same
day were considered 1 GNR event and classiﬁed as polymicrobial bacter-
emia, except for the purposes of the organism-speciﬁc analysis.
FQ-resistant GNR bacteremia was deﬁned as the isolation of a GNR or-
ganism that was either intermediate or resistant to levoﬂoxacin or cipro-
ﬂoxacin. Sensitivities to levoﬂoxacin and ciproﬂoxacin were used because
(1) sensitivities against these agents were routinely performed, and (2) FQ
resistance is known to exhibit a “class effect,” where a decrease in suscep-
tibility to 1 drug likely means a similar decrease in all FQs [15]. FQ sensi-
tivities were determined by the University of Washington Medical Center
Microbiology Laboratory using Kirby-Bauer or E-tests and interpreted using
current Clinical and Laboratory Standards Institute guidelines at the time of
GNR isolation [16]. Bacterial species that did not have current Clinical and
Laboratory Standards Institute breakpoints for FQs at the time of specimen
collection were excluded from resistance analyses. When evaluating FQ
resistance, events were included if a previously isolated organism became
resistant on follow-up blood cultures, even if those were within 14 days of
the initial culture. Similarly, polymicrobial bacteremia events were classiﬁed
as FQ-resistant event if any of the isolated GNRs were determined to be
intermediate or resistant to FQs, except for the purposes of the organism-
speciﬁc analysis, where the sensitivities of each organism were considered
separately.
Statistical Analysis
For the primary evaluation of GNR incidence, we considered only the
ﬁrst GNR bacteremia event per transplantation. The incidence rates of GNR
bacteremia and FQ-resistant GNR bacteremia during 30 and 100 days after
transplantationwere calculated for each calendar year interval. Each patient
contributed patient-days (PD) at risk from the day of transplantation until
death, retransplantation, 30 or 100 days after transplantation, or ﬁrst GNR
bacteremia event, whichever occurred ﬁrst. Changes in incidence rates over
time were assessed using a Poisson regression model, with time in 1-year
intervals as the main independent variable and count of a GNR bacteremia
event after transplantation as the dependent variable. PD at risk were
included as an offset term to account for the varying follow-up time among
transplantations. Incidence rate ratios (IRR) were used as the measure of
change. Clustered robust standard errors were used to account for the cor-
relation between transplantations of patients who underwent multiple
transplantations during our time period of interest.
Next, we conducted analyses considering all GNR bacteremia events for
each transplantation. In these analyses, each patient contributed PD at risk
from the day of transplantation until death, 30 or 100 days after trans-
plantation, or retransplantation, whichever occurred ﬁrst. The dependent
variable in this analysis was the total count of GNR bacteremia events after
transplantation. Changes in incidence rates over time were assessed using
similar methods to those described above.
For all analyses, estimated changes in incidence rates were ﬁrst calcu-
lated in unadjusted models to assess the average overall change regardless
of the mechanism. We then constructed models that included known risk
factors for GNR bacteremia. These covariates were selected a priori and
included age at transplantation, severity of underlying illness (low, medium,
and high), conditioning regimen score (nonmyeloablative, nonetotal body
irradiation, total body irradiation with 12 Gray (Gy), total body irradiation
with >12 Gy), presence of severe gut graft-versus-host disease (GVHD) 
grade 2, and graft type (bone marrow, peripheral blood, or cord blood).
Severity of underlying illnesses categories were deﬁned by outcomes pre-
viously observed at our center, whereas conditioning regimens were ﬁrst
divided into nonmyeloablative and myeloablative, with myeloablative
Table 1
Selected Characteristics of Adult Allogeneic HCT Transplantations by
Occurrence of GNR Bacteremia within 100 Days after Transplantation
Variable GNR Event No GNR Events
n ¼ 280 n ¼ 2026
Age, median (IQR), yr 53 (18) 51 (20)
Sex
Male 147 (52.5) 1216 (60.0)
Female 133 (47.5) 810 (40.0)
Race
Caucasian 215 (80.2) 1654 (85.0)
Black 10 (3.7) 28 (1.4)
Hispanic 16 (6.0) 59 (3.0)
Asian/Paciﬁc Islander 13 (4.9) 100 (5.1)
Native American 2 (.8) 18 (.9)
Other 12 (4.5) 87 (4.5)
Stem cell source
Bone marrow 44 (15.7) 273 (13.5)
Bone marrow and PBSC 2 (.7) 2.9 (.10)
PBSC 213 (76.1) 1643 (81.1)
Cord blood 21 (7.5) 108 (5.3)
Diagnosis
Acute leukemia 130 (46.4) 935 (46.2)
Multiple myeloma 16 (5.7) 114 (5.6)
Myelodysplastic syndrome 43 (15.4) 402 (19.8)
Non-Hodgkin lymphoma 36 (12.9) 210 (10.4)
Other 55 (19.6) 365 (18.0)
Underlying disease severity
Low 38 (13.6) 287 (14.2)
Medium 143 (51.1) 1013 (50.0)
High 99 (35.4) 726 (35.8)
Conditioning regimen score
Nonmyeloablative 125 (44.6) 827 (40.8)
Nonetotal body irradiation 77 (27.5) 664 (32.8)
Total body irradiation with 12 Gy 67 (23.9) 471 (23.3)
Total body irradiation with >12 Gy 11 (3.9) 64 (3.2)
Severe gut GVHD (grade 2)*
Yes 61 (21.8) 175 (8.7)
No 219 (78.2) 1845 (91.3)
IQR indicates interquartile range; PBSC, peripheral blood stem cells.
Data presented are n (%) unless otherwise indicated.
* Number does not add to n because of missing data.
Figure 1. (A) Incidence rate of ﬁrst GNR bacteremia event, by transplantation
year, 2003 to 2012. (B) Incidence rate of all GNR bacteremia events, by
transplantation year, 2003 to 2012.
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ining the main results, we elected to conduct post hoc exploratory analyses
to quantify the trends of GNR bacteremia and FQ-resistant GNR bacteremia
incidence rates between 2003 and 2009 and separately for 2009 to 2012.
These analyses were conducted for ﬁrst events, all events, day 0 to 30, and
day 0 to 100. We also evaluated trends in the organism-speciﬁc incidence
rates of FQ-resistant variants of the 3 most commonly isolated GNR or-
ganisms: Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aerugi-
nosa. Changes in incidence rates over time were assessed using similar
methods.
Last, the 30-day all-cause cumulative mortality was compared between
patients who developed FQ-resistant GNR bacteremia and those who
developed FQ-sensitive GNR bacteremia using Kaplan-Meier estimates and
the log-rank test. Cox proportional hazards regression models were used to
compare the risk of death during 30 days after the ﬁrst positive GNR blood
culture. These analyses were performed both without adjustment for any
covariates and with adjustment for underlying disease severity, condition-
ing regimen score, and age at transplantation. All analyses were performed
using Stata version 13 (StataCorp, College Station, TX).RESULTS
Of the 2306 transplantations included in this cohort, 280
(12.1%) experienced at least 1 GNR bacteremia event during
the ﬁrst 100 days after transplantation; 82 of these events
occurred between days 0 and 30 and 198 occurred between
days 31 and 100. In the ﬁrst event analysis of patients with
available resistance data (n ¼ 255), there were 88 of 255
(34.5%) FQ-resistant events and 167 of 255 (65.5%) FQ-
sensitive events; 25 GNR events had no resistance data
available. The selected demographic and clinicalcharacteristics of patients who experienced a GNR bacter-
emia event and thosewho did not were very similar, with the
exception that patients who experienced GNR bacteremia
were more likely to have severe gut GVHD (Table 1).Time Trends in Incidence Rate of All GNR Bacteremia
When including only the ﬁrst GNR bacteremia event per
transplantation, the overall incidence rate of GNR bacteremia
was 1.36 events per 1000 PD (95% conﬁdence interval [CI],
1.21 to 1.53); the incidence rate between days 0 and 30 was
1.18 per 1000 PD (95% CI, .94 to 1.47) and between days 31 an
100 was 1.46 per 1000 PD (95% CI, 1.26 to 1.67). Overall
incidence rates varied over time, starting at .86 events per
1000 PD in 2003 (95% CI, .52 to 1.34), peaking at 2.33 events
per 1000 PD in 2009 (95% CI, 1.71 to 3.11), and declining to its
lowest in 2012 at .63 events per 1000 PD (95% CI, .34 to 1.08)
(Figure 1A). On average, the incidence rate of GNR bacter-
emia increased annually between 2003 and 2012 by 1%,
although this trend was not statistically signiﬁcant (IRR, 1.01;
95% CI, .98 to 1.05) (Table 2).
A post hoc analysis showed an average annual increase of
the incidence rate of GNR bacteremia of 16% (IRR,1.16; 95% CI,
1.09 to 1.25) between 2003 and 2009 and an average annual
decrease of 32% (IRR, .68; 95% CI, .56 to .80) between 2009
and 2012. When only considering events that occurred be-
tween days 0 and 30 after transplantation, all trends over
timewere in the same direction as described above, but none
were statistically signiﬁcant (Table 2).
Table 2
Unadjusted and Adjusted Time Trends in Incidence Rates of GNR Bacteremia, 2003 to 2012
Overall FQ-Resistant
2003-2012 2003-2009 2009-2012 2003-2012 2003-2009 2009-2012
Unadjusted Unadjusted
IRR (95% CI) IRR (95% CI)
First event
Overall (0-100) 1.01 (.98-1.05) 1.16 (1.09-1.25) .68 (.56-.80) 1.01 (.95-1.08) 1.18 (1.04-1.33) .62 (.45-.86)
Month 1 (0-30) 1.02 (.95-1.10) 1.05 (.92-1.20) .82 (.62-1.10) 1.08 (.96-1.21) 1.12 (.89-1.40) .87 (.57-1.32)
Multiple events
Overall (0-100) 1.02 (.98-1.06) 1.18 (1.10-1.26) .69 (.57-.82) 1.00 (.94-1.07) 1.17 (1.03-1.33) .62 (.46-.85)
Month 1 (0-30) 1.03 (.96-1.11) 1.08 (.94-1.23) .86 (.64-1.15) 1.08 (.96-1.21) 1.12 (.89-1.40) .87 (.57-1.32)
Adjusted Adjusted
aIRR (95% CI)* aIRR (95% CI)*
First Event
Overall (0-100) 1.00 (.97-1.04) 1.14 (1.06-1.23) .67 (.55-.80) 1.00 (.93-1.07) 1.14 (1.00-1.30) .62 (.45-.87)
Month 1 (0-30) 1.00 (.92-1.08) .97 (.84-1.12) .86 (.63-1.18) 1.04 (.91-1.18) 1.00 (.78-1.28) .88 (.55-1.40)
Multiple events
Overall (0-100) 1.02 (.98-1.05) 1.16 (1.08-1.25) .68 (.56-.82) .99 (.93-1.06) 1.13 (1.00-1.28) .63 (.46-.86)
Month 1 (0-30) 1.01 (.93-1.09) 1.00 (.87-1.16) .90 (.65-1.25) 1.04 (.91-1.18) 1.00 (.78-1.28) .88 (.56-1.38)
aIRR indicates adjusted incidence rate ratio.
* Adjusted for underlying disease severity, conditioning regimen score, presence of severe gut GVHD, graft type, and age at transplantation.
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meaningfully change the associations observed in unad-
justed analyses (Table 2). Results from the multiple events
analyses demonstrated similar results, with minimal in-
creases in the incidence rates of GNR bacteremia compared
with the ﬁrst event analysis (Table 2, Figure 1B).Time Trends in Incidence Rate of FQ-resistant GNR
Bacteremia
The incidence rate of FQ-resistant GNR bacteremia
generally displayed similar patterns. In the ﬁrst event anal-
ysis, the overall incidence rate of FQ-resistant GNR bacter-
emia was .43 events per 1000 PD (95% CI .34 to .53). The
incidence rates varied over time, starting at .23 events per
1000 PD in 2003 (95% CI, .07 to .53), peaking at .81 events per
1000 PD in 2009 (95% CI, .46 to 1.32), and decreasing to .19
events per 1000 PD in 2012 (95% CI, .05 to .50) (Figure 1A). On
average, the incidence rate of FQ-resistant GNR bacteremia
increased annually between 2003 and 2012 by 1%, although
this trend was not signiﬁcant (IRR, 1.01; 95% CI, .95 to 1.08)
(Table 2).
A post hoc analysis showed an average annual increase of
the incidence rate of FQ-resistant GNR bacteremia of 18%
(IRR, 1.18; 95% CI, 1.04 to 1.33) between 2003 and 2009 and
an average annual decrease of 38% (IRR, .62; 95% CI, .45 to
.86) between 2009 and 2012. When only considering events
that occurred between days 0 and 30 after transplantation,
all trends over time were in the same direction as described
above, but none were statistically signiﬁcant (Table 2).
Adjusting for known risk factors for bacteremia did notTable 3
Most Common GNR Isolated from Blood Cultures and Their Respective Fluoroquin
All 2003 2004 2005 2006
n %S* n %S n %S n %S n %S
E. coli 54 27.8 1 100 6 16.7 2 50 9 11.1
K. pneumoniae 48 62.5 0 e 1 100 5 60 10 90.0
P. aeruginosa 43 58.1 2 0 7 71.4 8 37.5 3 66.7
S. maltophilia 40 67.5 2 0 1 0 4 50 3 100
K. oxytoca 34 85.3 2 50 2 100 7 85.7 2 100
E. cloacae 27 85.2 2 100 1 100 4 100 3 100
* Percent sensitive to ﬂuoroquinolones.meaningfully change the associations observed in unad-
justed analyses (Table 2). Results from the multiple events
analysis again found similar results, including minimal
overall increases in the incidence rates of FQ-resistant GNR
bacteremia compared with the ﬁrst event analysis (Table 2,
Figure 1B). The 3 most commonly isolated organisms were
E. coli, K. pneumoniae, and P. aeruginosa,which demonstrated
overall FQ-sensitivity of 27.8%, 62.5%, and 58.1%, respectively
(Table 3); individual analyses of annual trends in the inci-
dence rates of FQ-resistant variants of these 3 organisms
showed no signiﬁcant annual trends between 2003 and 2012
(IRR,1.08; 95% CI, .96 to 1.20; IRR,1.09; 95% CI, .99 to 1.19; IRR,
.91; and 95% CI; .77 to 1.08, respectively).Survival Analysis by FQ Resistance
Patients who had an initial FQ-resistant GNR bacteremia
event had a signiﬁcantly higher 30-day post-event cumula-
tive mortality than patients who experienced a FQ-sensitive
event (20.8% versus 9.6%, P ¼ .018) (Figure 2). In an unad-
justed survival analysis, patients with FQ-resistant GNR
bacteremia had an increased risk of death through 30-days
post-GNR isolation than patients with FQ-sensitive bacter-
emia (hazard ratio, 2.23; 95% CI, 1.13 to 4.43). This association
persisted after adjustment for severity of underlying illness,
conditioning regimen score, and age at transplantation
(hazard ratio, 2.11; 95% CI, 1.06 to 4.23).DISCUSSION
In this large, single-center, longitudinal retrospective
study, we examined trends in the incidence of GNRolone Sensitivities by Year, 2003 to 2012
2007 2008 2009 2010 2011 2012
n %S n %S n %S n %S n %S n %S
10 50.0 2 50.0 7 28.6 8 37.5 6 0 3 0
3 66.7 9 44.4 9 22.2 6 66.7 2 100 3 100
2 50 6 93.3 7 57.1 3 66.7 2 50 3 66.7
9 55.6 5 60.0 6 83.3 2 100 7 100 1 0
4 100 3 100 8 87.5 1 100 5 60 0 e
4 100 7 71.4 6 66.7 0 e 0 e 1 100
0.
00
0.
25
0.
50
0.
75
1.
00
0 10 20 30
Days since isolation of organism
 Sensitive  Resistant
Kaplan-Meier Curves by FQ-resistance
Figure 2. Kaplan-Meier survival estimates 30 days after ﬁrst infection, by FQ-
resistance status.
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allogeneic HCT recipients over a decade during which levo-
ﬂoxacin was used for neutropenic prophylaxis. We found
that, on average, there was no signiﬁcant trend in the inci-
dence rates of GNR bacteremia and FQ-resistant GNR
bacteremia between 2003 and 2012 in this population. In
post hoc analyses, we found that the incidence rates of GNR
bacteremia and FQ-resistant GNR bacteremia increased
annually between 2003 and 2009 and then decreased be-
tween 2009 and 2012. An organism-speciﬁc analysis did not
reveal any signiﬁcant trends in the incidence rates of FQ-
resistant E. coli, K. pneumoniae, or P. aeuroginosa, the 3
most common organisms in this cohort. Lastly, these data
demonstrate that patients who developed bacteremia from
FQ-resistant GNRs had higher 30-day mortality than those
who developed bacteremia from FQ-sensitive GNRs.
Other centers have described rising rates of GNR in-
fections in HCT patients, but few studies have studied trends
in GNR bacteremia over time or assessed such data after a
major change in neutropenic antibiotic prophylaxis. The
ﬁndings of studies that quantiﬁed this association have been
inconsistent, with at least 1 center reporting signiﬁcantly
increasing rates of GNR bacteremia during use of levoﬂoxacin
prophylaxis [1] and another reporting no signiﬁcant change
[10]. Available data on the issue of FQ-resistance in patient
populations receiving FQ prophylaxis also varies between
centers. Some have described nonsigniﬁcant increases in the
proportion of GNR isolates that are FQ resistant during an era
of FQ prophylaxis [1,3], whereas others, including a previous
study at our center, reported no changes in FQ resistance
after initiation of levoﬂoxacin prophylaxis [9,12]. In contrast,
other centers have described signiﬁcantly increasing rates of
FQ-resistant GNR during FQ prophylaxis [10,18,19], including
1 that only measured FQ-resistant E. coli [18]. Our data are
most consistent with studies that identiﬁed no signiﬁcant
overall increase in GNR bacteremia or FQ-resistant GNR
bacteremia over time. To our knowledge, none of these
studies have addressed survival differences between HCT
patients who developed bacteremia with FQ-resistant and
FQ-sensitive GNRs; however, FQ resistance has been identi-
ﬁed as an independent risk factor for death after infection in
other populations [13].
The observed patterns of incidence rates in this study
were somewhat unexpected, as prior data from our centerindicated that rates of GNR bacteremia had been increasing
[11]. We hypothesized that this increase might be associ-
ated with our widespread use of levoﬂoxacin prophylaxis,
especially if the increasing rates of GNR bacteremia were
accompanied by increasing rates of FQ-resistant GNRs. Our
post hoc analyses conﬁrmed this increase through 2009,
but rates of GNR bacteremia steeply decreased between
2009 and 2012. There are likely several contributing factors
to the decrease in GNR bacteremia events after 2009 in this
population. Several infection control interventions were
implemented between 2009 and 2010, including the initi-
ation of chlorhexidine gluconate cloths for daily bathing in
January 2010, the development and implementation of a
new line bundle also in January 2010, adoption of “scrub
the hub” [20] as a standardized protocol in September
2010, and a switch to chlorhexidine gluconateeimpreg-
nated dressings in February 2009. Because such in-
terventions have been associated with decreased rates of
bloodborne infections [21-23], it is possible that, together,
they contributed to the decrease in GNR bacteremia be-
tween 2009 and 2012. Temporal changes in GVHD inci-
dence and therapy, such as alterations in glucocorticoid use
for initial GVHD treatment [24], may also have contributed
to the observed decrease in GNR bacteremia. Of note, the
post-2009 decline in the incidence of GNR bacteremia was
not appreciably affected by adjusting for conditioning
regimen (Table 2), suggesting that the decline could not be
attributed to a change in the number of patients receiving
reduced-intensity conditioning.
It is also important to acknowledge that standard prac-
tice changed in 2010 to discontinue collection of an extra set
of blood cultures that were held for yeast and fungi. With
improvements in microbiologic techniques, such methods
provided no additional beneﬁt in isolating fungal pathogens
in these patients. It is possible that these extra cultures
cultivated bacterial growth, and their discontinuation could
have contributed to the decrease in isolation of GNR or-
ganisms. Additionally, the microbiology laboratory changed
their blood culture system in 2010, potentially resulting in
differential isolation of organisms. To address these issues,
we examined the number of blood cultures ordered be-
tween 2003 and 2012, and these data demonstrated a
similar time trend as the incidence rates of GNR bacteremia,
suggesting that these laboratory changes did not contribute
signiﬁcantly to our results (data not shown). Although we
hypothesize that many of the aforementioned factors
inﬂuenced the observed recent decline in rates of GNR
bacteremia, this study was not designed to directly attribute
changes in incidence to any of these infection control in-
terventions or laboratory variations.
Most importantly, we did not observe an increase in FQ-
resistant GNR bacteremia with widespread use of levo-
ﬂoxacin as neutropenic prophylaxis in this population. One
reason for this could be shorter exposure intervals to lev-
oﬂoxacin in the overall population driven by a gradual
increase in the number of nonmyeloablative trans-
plantations over time. Another possible explanation is that
our patients receive a higher dose of levoﬂoxacin for pro-
phylaxis (750 mg) than that tested in placebo-controlled
trials (500 mg) [25,26]. FQs are unique in that they are
synthetic antibiotics, and although it was thought that they
might be more insulated from resistance issues, overuse in
medicine and in agriculture has led to reports of increasing
rates of FQ resistance worldwide [27]. Lack of a signiﬁcant
increase in FQ resistance observed in this study suggests
A. Miles-Jay et al. / Biol Blood Marrow Transplant 21 (2015) 539e545544that levoﬂoxacin may continue to be a viable neutropenic
prophylaxis agent in this population.
Lastly, these data show that patients with FQ-resistant
GNR bacteremia had a greater than 2-fold increased risk of
death within 30-days after infection compared with patients
with FQ-sensitive GNR bacteremia. This association persisted
even after adjusting for underlying disease severity, type of
conditioning regimen, and age at transplantation, suggesting
that FQ resistance may be an independent risk factor for
death in patients with GNR bacteremia. One mechanism that
may explain such differences is that patients with resistant
infections experience a delay in receiving adequate antimi-
crobial therapy. Previous studies have demonstrated an
association between administration of inadequate antimi-
crobial treatment and mortality [28,29]. Another mechanism
might be that organisms that demonstrate lower rates of FQ-
sensitivity, such as P. aeruginosa (Table 3), have been shown
to have associated increased mortality [30]. Further research
is needed to elucidate risk factors for the development of FQ-
resistant infections, to allow for prompt identiﬁcation and
treatment of these patients. Overall, these data highlight the
serious nature of antimicrobial resistance and the impor-
tance of continued monitoring of FQ resistance trends in HCT
recipients and other high-risk populations.
The retrospective and observational nature of this study
imposes limits on the interpretation of our data. There are
likely variables that have changed over time and that inﬂu-
ence GNR bacteremia rates or FQ resistance for which we
could not adjust. One speciﬁc unmeasured variable was the
proportion of the population that did not receive any early
post-transplantation levoﬂoxacin. However, we estimate
that this subset of the population would make up less than
5% of this cohort, and we do not feel that minor changes in
that proportion over time would appreciably change our
results. Additionally, there were organisms that lacked FQ
sensitivity data and could not be included in the FQ-
resistance analysis, and it is possible that changes in the
incidence of these unclassiﬁable organisms over time may
have had a minimal effect on our results. Finally, these data
only reﬂect the experience of a single center and may not be
generalizable to other institutions, as regional variances in
transplantation conditioning and antimicrobial therapy and
prevalence of FQ resistance could affect GNR bacteremia
trends at other centers. Strengths of this study include the
large sample size and the valuable long-term longitudinal
data, which inform evidence-based decisions about use of FQ
prophylaxis at our center.
In summary, these data demonstrate that rates of FQ-
resistant GNR bacteremia have not signiﬁcantly increased
during an era of levoﬂoxacin prophylaxis in adult allogeneic
HCT recipients at our large comprehensive cancer. Recent de-
creases in incidence ratesofGNRbacteremiawerepotentiallya
result of a combination of center-wide changes, including
several infection control interventions. Although there is no
evidence that levoﬂoxacin prophylaxis is associated with an
increase in FQ-resistant bacteremia in HCT recipients at our
center, the increased mortality associated with FQ-resistant
GNR bacteremia reinforces the importance of monitoring
emerging FQ resistance in this high-risk population.
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